Syncona Investee Freeline Therapeutics Files For Possible US Listing
Syncona Investee Freeline Therapeutics Files For Possible US Listing
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreFri, 26th Mar 2021 07:59
Syncona Investee Freeline Therapeutics Files For Possible US Listing
Read more(Sharecast News) - Healthcare investor Syncona said its portfolio company Freeline Therapeutics has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering (IPO).
Read moreSyncona's Investee Freeline Publishes Further Data For FLT180a
Read moreSyncona Investee Freeline Raises USD120 Million And Mulls US Listing
Read more(Sharecast News) - Healthcare investment and development company Syncona announced on Tuesday that Freeline Therapeutics - a biotechnology company focussed on developing curative gene therapies for chronic systemic diseases - has raised a further $80m (£65.09m) from specialist global institutional investors in an expanded series C round.
Read moreDIRECTOR DEALINGS: Syncona Non-Exec Reverberi Buys GBP50,000 In Shares
Read moreFormer Bayer Healthcare Chief Medical Officer Malik Joins Syncona
Read moreSyncona Annual Assets Take Hit From Autolus Value But Likes Portfolio
Read more(Sharecast News) - Syncona reported a 13% fall in net asset value as the value of its life sciences division dropped by a quarter in its most recent financial year.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreSyncona Investee Achilles Therapeutics Starts Melanoma Therapy Trial
Read more(Sharecast News) - Syncona announced on Friday that its portfolio company, Achilles Therapeutics, has dosed the first patient in a phase 1 and 2 clinical study of its clonal neoantigen T cell (cNeT) therapy, in patients with recurrent or metastatic malignant melanoma.
Read moreSyncona Makes USD51 Million Investment Into SwanBio Therapeutics
Read more(Sharecast News) - Syncona announced a new $51m (?41.39m) commitment in an expanded $77m series A round of financing by SwanBio Therapeutics on Thursday.
Read moreSyncona, Arix Note US FDA Acceptance Of Autolus Drug Application
Read more